160 related articles for article (PubMed ID: 6879005)
41. [The national vaccination program against measles].
Cohen H; Brouwer R; Bijkerk H; Phaff JM
Ned Tijdschr Geneeskd; 1978 Jan; 122(2):46-51. PubMed ID: 619292
[No Abstract] [Full Text] [Related]
42. Measles vaccines.
Griffin DE; Pan CH; Moss WJ
Front Biosci; 2008 Jan; 13():1352-70. PubMed ID: 17981635
[TBL] [Abstract][Full Text] [Related]
43. WHO-supported comparative studies of attenuated live measles virus vaccines.
Cockburn WC; Pecenka J; Sundaresan T
Bull World Health Organ; 1966; 34(2):223-31. PubMed ID: 4161187
[TBL] [Abstract][Full Text] [Related]
44. [Comparative testing of live measles vaccines manufactured in France, Japan, and Russia].
Popov VF; Iunasova TN; Povalikhina LV; Shitikova OIu
Vopr Virusol; 1995; 40(6):253-7. PubMed ID: 8686260
[TBL] [Abstract][Full Text] [Related]
45. Development of extremely attenuated live measles virus vaccine (CAM-EX).
Ueda S; Takahashi M; Kurimura T; Minekawa Y; Suzuki N
Biken J; 1972 Sep; 15(3):173-7. PubMed ID: 4643692
[No Abstract] [Full Text] [Related]
46. [Comparative studies of measles vaccines prepared from further attenuated strains Schwarz and SEVAC].
Adam E; Fosenbauerová E; Domorázková E; Kratochvílová M; Kubátová E; Mares I; Drevo M; Svandová E
Cesk Pediatr; 1968 Jul; 23(7):581-93. PubMed ID: 5681931
[No Abstract] [Full Text] [Related]
47. Serological effects of Edmonston-Zagreb, Schwarz, and AIK-C measles vaccine strains given at ages 4-5 or 8-10 months.
Tidjani O; Grunitsky B; Guérin N; Lévy-Bruhl D; Lecam N; Xuereff C; Tatagan K
Lancet; 1989 Dec; 2(8676):1357-60. PubMed ID: 2574304
[TBL] [Abstract][Full Text] [Related]
48. The status of measles after five years of mass vaccination in the USSR.
Burgasov PN; Andzaparidze OG; Popov VF
Bull World Health Organ; 1973; 49(6):571-6. PubMed ID: 4548384
[TBL] [Abstract][Full Text] [Related]
49. CHRONOVAC VOYAGEUR: A study of the immune response to yellow fever vaccine among infants previously immunized against measles.
Goujon C; Gougeon ML; Tondeur L; Poirier B; Seffer V; Desprès P; Consigny PH; Vray M;
Vaccine; 2017 Oct; 35(45):6166-6171. PubMed ID: 28958813
[TBL] [Abstract][Full Text] [Related]
50. Vaccination of children in Japan.
Nishi M; Miyake H; Ito Y; Kagiichi S; Kimura M; Suzuki A; Takaoka A; Tago N; Nagase K
Asia Pac J Public Health; 1990; 4(2-3):128-31. PubMed ID: 2278761
[TBL] [Abstract][Full Text] [Related]
51. Vaccination against measles: a clinical trial of live measles vaccine given alone and live vaccine preceded by killed vaccine. A report to the Medical Research Council by the Measles Vaccines Committee.
Br Med J; 1966 Feb; 1(5485):441-6. PubMed ID: 5902680
[No Abstract] [Full Text] [Related]
52. A paediatric vaccination vector based on live attenuated measles vaccine.
Lorin C; Combredet C; Labrousse V; Mollet L; Desprès P; Tangy F
Therapie; 2005; 60(3):227-33. PubMed ID: 16128264
[TBL] [Abstract][Full Text] [Related]
53. [Clinical reactions and antibody responses of measles-susceptible healthy children to the live measles "AIK-C" vaccine(chick embryo tissue culture type)].
Okayama T
Kansenshogaku Zasshi; 1975 Apr; 49(4):150-8. PubMed ID: 811729
[No Abstract] [Full Text] [Related]
54. The development and the study of live measles vaccine from highly attenuated strain Enders-Schwarz-Chumakov (ESC).
Chumakov MP; Voroshilova MK; Grachev VP; Dzagurov SG; Sinyak KM
Prog Immunobiol Stand; 1967; 3():194-5. PubMed ID: 5379939
[No Abstract] [Full Text] [Related]
55. Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age.
Paunio M; Hedman K; Davidkin I; Valle M; Heinonen OP; Leinikki P; Salmi A; Peltola H
Epidemiol Infect; 2000 Apr; 124(2):263-71. PubMed ID: 10813152
[TBL] [Abstract][Full Text] [Related]
56. Experimental study of a further attenuated live measles vaccine of the Sugiyama strain in Iran.
Mirchamsy H; Shafyi A; Rafyi MR; Bahrami S; Nazari P; Fatemie S
J Hyg (Lond); 1974 Apr; 72(2):273-9. PubMed ID: 4522721
[TBL] [Abstract][Full Text] [Related]
57. [Measles epidemic and investigation of the vaccination history in Chiba Prefecture in 2000. A report from Chiba epidemiological surveillance of tuberculosis and infectious diseases].
Ogura M; Ichimura H
Kansenshogaku Zasshi; 2001 Aug; 75(8):686-91. PubMed ID: 11558131
[TBL] [Abstract][Full Text] [Related]
58. Trial of a reduced dose of measles vaccine in Nigerian children.
Wallace RB; Landrigan PJ; Smith EA; Pifer J; Teller B; Foster SO
Bull World Health Organ; 1976; 53(4):361-4. PubMed ID: 1086728
[TBL] [Abstract][Full Text] [Related]
59. Measles antibody levels after vaccination with Edmonston-Zagreb and Schwarz measles vaccine at 9 months or at 9 and 18 months of age: a serological study within a randomised trial of different measles vaccines.
Martins C; Garly ML; Bale C; Rodrigues A; Benn CS; Whittle H; Aaby P
Vaccine; 2013 Nov; 31(48):5766-71. PubMed ID: 23994379
[TBL] [Abstract][Full Text] [Related]
60. [Clinical and serological studies on a further attenuated live measles virus AIK vaccine].
Nino K
Kansenshogaku Zasshi; 1973 Apr; 47(4):116-24. PubMed ID: 4199824
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
